Trial of Cannabidiol to Treat Severe Behavior Problems in Children With Autism

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

August 30, 2025

Study Completion Date

December 31, 2025

Conditions
AutismAutism Spectrum Disorder
Interventions
DRUG

Epidiolex

"While in the intervention arm subjects will receive EPIDIOLEX, an oral purified CBD solution developed by GW Pharmaceuticals. The formulation is a 100 mg/mL solution, which allows for easy dose titration and administration even to young children. EPIDIOLEX is naturally-derived CBD, and has been found to have a purity of over 98%. The solution includes a sweetener to make it palatable. Dosing is dependent upon each subject's weight.~The dosage will be titrated over time as follows:~Week 1: 5 mg/kg/day, divided into 2 doses Week 2: 10 mg/kg/day, divided into 2 doses Weeks 3-8: 20 mg/kg/day, divided into 2 doses If a child's weight changes by greater than 2 kg during the study, the dose will be adjusted to reflect the weight change."

DRUG

placebo oral solution

"GW has developed a placebo that is identical in color and taste, and will be administered in the same volume as the CBD, so that parents and investigators should not be able to detect differences between the 2 treatments. Dosing is dependent upon each subject's weight.~The dosage will be titrated as follows:~Week 1: 5 mg/kg/day, divided into 2 doses Week 2: 10 mg/kg/day, divided into 2 doses Weeks 3-8: 20 mg/kg/day, divided into 2 doses If a child's weight changes by greater than 2 kg during the study, the dose will be adjusted to reflect the weight change."

Trial Locations (1)

92093

University of California San Diego, La Jolla

All Listed Sponsors
collaborator

Wholistic Research and Education Foundation

UNKNOWN

collaborator

Center for Medicinal Cannabis Research

OTHER

lead

University of California, San Diego

OTHER